深圳大学Peng Huang团队的最新研究提出，仿生纳米乳协同光动力学的免疫治疗低氧乳腺肿瘤。 相关论文于2021年2月8日发表在《德国应用化学》杂志上。

该工作中，研究人员开发了一种仿生纳米乳剂，其伪装了可表达PD-1的细胞膜，用于协同光动力免疫治疗低氧性乳腺肿瘤。纳米乳的全氟碳可以提供氧气，作为PDT对抗缺氧肿瘤的动力。

此外，共传递光敏剂和PD-1蛋白（取代PD - L1抗体）实现了PDT和免疫治疗的协同效应。协同光动力免疫疗法通过促进树突状细胞的成熟和肿瘤对细胞毒性T淋巴细胞的浸润，以机械方式完全抑制了原发性和远距离皮下膜4T1肿瘤。

据介绍，光动力疗法（PDT）通常用作“原位疫苗”，用于增强PD-1/PD-L1抗体的响应速率。不幸的是，这些抗体的高成本和不良反应，以及实体肿瘤的缺氧状态限制了协同光动力免疫治疗的效果。

附：英文原文

Title: Biomimetic nanoemulsion for synergistic photodynamic‐immunotherapy against hypoxic breast tumor

Author: Peng Huang, Yifan Zhang, Yunyan Liao, Qinan Tang, Jing Lin

Issue&Volume: 2021-02-08

Abstract: Photodynamic therapy (PDT) is commonly used as an “  in situ  vaccine” to enhance the response rate of PD‐1/PD‐L1 antibodies. Unfortunately, the high costs and adverse effects of these antibodies, and the hypoxic state of solid tumors limits the efficacy of synergistic photodynamic–immunotherapy. Here, we developed a biomimetic nanoemulsion camouflaged with a PD‐1‐expressing cell membrane for synergistic photodynamic–immunotherapy against hypoxic breast tumors. The perfluorocarbon of the nanoemulsion could provide oxygen as the source of PDT against hypoxic tumors. Moreover, co‐delivering a photosensitizer and the PD‐1 protein (substituting for a PD‐L1 antibody) achieves the synergy effect of PDT and immunotherapy. Synergistic photodynamic–immunotherapy completely inhibited primary and distant subcutaneous 4T1 tumors, mechanistically by boosting the maturation of dendritic cells and tumor infiltration of cytotoxic T lymphocytes.

DOI: 10.1002/anie.202015590

Source: https://onlinelibrary.wiley.com/doi/10.1002/anie.202015590